Molecular biomarkers for quantitative and discrete COPD phenotypes.

Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disorder with complex pathological features and largely unknown etiology. The identification of biomarkers for this disease could aid the development of methods to facilitate earlier diagnosis, the classification of disease subtypes, and provide a means to define therapeutic response. To identify gene expression biomarkers, we completed expression profiling of RNA derived from the lung tissue of 56 subjects with varying degrees of airflow obstruction using the Affymetrix U133 Plus 2.0 array. We applied multiple, independent analytical methods to define biomarkers for either discrete or quantitative disease phenotypes. Analysis of differential expression between cases (n = 15) and controls (n = 18) identified a set of 65 discrete biomarkers. Correlation of gene expression with quantitative measures of airflow obstruction (FEV(1)%predicted or FEV(1)/FVC) identified a set of 220 biomarkers. Biomarker genes were enriched in functions related to DNA binding and regulation of transcription. We used this group of biomarkers to predict disease in an unrelated data set, generated from patients with severe emphysema, with 97% accuracy. Our data contribute to the understanding of gene expression changes occurring in the lung tissue of patients with obstructive lung disease and provide additional insight into potential mechanisms involved in the disease process. Furthermore, we present the first gene expression biomarker for COPD validated in an independent data set.

[1]  P. Sebastiani,et al.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2007, Nature Medicine.

[2]  Christoph Lange,et al.  The SERPINE2 gene is associated with chronic obstructive pulmonary disease. , 2006, American journal of human genetics.

[3]  Thomas J. Mariani,et al.  Epithelial cell PPARγ contributes to normal lung maturation , 2006 .

[4]  E. Silverman.  Progress in chronic obstructive pulmonary disease genetics. , 2006, Proceedings of the American Thoracic Society.

[5]  Soumyaroop Bhattacharya,et al.  Epithelial cell PPAR[gamma] contributes to normal lung maturation. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[7]  P. Sebastiani,et al.  Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. , 2005, Physiological genomics.

[8]  Frank Kee,et al.  The prevalence of obstructive lung disease in a general population sample: The NICECOPD study , 2005, European Journal of Epidemiology.

[9]  Irina Petrache,et al.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. , 2004, The Journal of clinical investigation.

[10]  Naftali Kaminski,et al.  Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Celli,et al.  Gene expression profiling of human lung tissue from smokers with severe emphysema. , 2004, American journal of respiratory cell and molecular biology.

[12]  P. Barnes,et al.  Prospects for new drugs for chronic obstructive pulmonary disease , 2004, The Lancet.

[13]  Gregory P Cosgrove,et al.  Emphysema lung tissue gene expression profiling. , 2004, American journal of respiratory cell and molecular biology.

[14]  Gang Liu,et al.  Effects of cigarette smoke on the human airway epithelial cell transcriptome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[16]  Guidel Ines,et al.  Expression profiling — best practices for data generation and interpretation in clinical trials , 2004, Nature Reviews Genetics.

[17]  P. Sebastiani,et al.  Bayesian Machine Learning and Its Potential Applications to the Genomic Study of Oral Oncology , 2003, Advances in dental research.

[18]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[19]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[20]  Soumyaroop Bhattacharya,et al.  A classification-based machine learning approach for the analysis of genome-wide expression data. , 2003, Genome research.

[21]  James Lyons-Weiler,et al.  Overcoming confounded controls in the analysis of gene expression data from microarray experiments. , 2003, Applied bioinformatics.

[22]  Edwin K Silverman,et al.  Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. , 2002, American journal of human genetics.

[23]  Steven D Shapiro,et al.  Expression profiling of the developing mouse lung: insights into the establishment of the extracellular matrix. , 2002, American journal of respiratory cell and molecular biology.

[24]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[25]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Miller,et al.  HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. , 2001, The American journal of pathology.

[27]  Alan D. Lopez.  THE GLOBAL BURDEN OF DISEASE 1990-2020 , 2001 .

[28]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Zou,et al.  Expression of Egr-1 in late stage emphysema. , 2000, The American journal of pathology.

[30]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[31]  P. Brown,et al.  Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T L Petty,et al.  The worldwide epidemiology of chronic obstructive pulmonary disease. , 1996, Current opinion in pulmonary medicine.

[33]  R. Carrell,et al.  SMOKING, LUNG FUNCTION, AND α1-ANTITRYPSIN DEFICIENCY , 1985, The Lancet.

[34]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[35]  C. Larsson.  Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. , 2009, Acta medica Scandinavica.

[36]  S. Eriksson,et al.  PULMONARY EMPHYSEMA AND ALPHA1-ANTITRYPSIN DEFICIENCY. , 2009, Acta medica Scandinavica.